FrancophonIA/ELRC3.0 huggingface dataset:
English: Ultibro Breezhaler has been studied in two main studies involving a total of 2,667 patients with COPD.
Estonian: Ravimit Ultibro Breezhaler uuriti kahes põhiuuringus, kus osales kokku 2667 kroonilise obstruktiivse kopsuhaigusega patsienti.
English: In patients with severely reduced kidney function Ultibro Breezhaler should only be used after a careful benefit-risk assessment.
Estonian: Neerude raske talitlushäirega patsiendid tohivad ravimit Ultibro Breezhaler kasutada ainult pärast kasulikkuse ja riski hoolikat hindamist.
English: Ultibro Breezhaler also increased FEV1 by 70 ml more than indacaterol alone and 90 ml more than glycopyrronium alone.
Estonian: Ultibro Breezhaler suurendas FEV1 väärtust 70 ml võrra rohkem kui ainult indakaterool ja 90 ml võrra rohkem kui ainult glükopürroonium.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ultibro Breezhaler, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Ultibro Breezhaleri ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavate ettevaatusmeetmete teave.
English: The first study showed that treatment with Ultibro Breezhaler was more effective than placebo and increased FEV1 by an average of 200 ml more.
Estonian: Esimeses uuringus oli ravi Ultibro Breezhaleriga efektiivsem kui platseeboga ja suurendas FEV1 väärtust keskmiselt 200 ml võrra.
English: The effects of Ultibro Breezhaler when used to relieve symptoms of COPD were clinically meaningful.
Estonian: Ultibro Breezhaleri toimed kasutamisel kroonilise obstruktiivse kopsuhaiguse sümptomite leevendamisel olid kliiniliselt olulised.
English: Other information about Ultibro Breezhaler
Estonian: Muu teave Ultibro Breezhaleri kohta
English: This is a summary of the European public assessment report (EPAR) for Ultibro Breezhaler.
Estonian: See on ravimi Ultibro Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
English: It is not intended to provide practical advice on how to use Ultibro Breezhaler.
Estonian: Hindamisaruandes ei anta Ultibro Breezhaleri kasutamise praktilisi nõuandeid.
English: For practical information about using Ultibro Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ultibro Breezhaleri kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Ultibro Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ultibro Breezhaleriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Ultibro Breezhaler and what is it used for?
Estonian: Mis on Ultibro Breezhaler ja milleks seda kasutatakse
English: Indacaterol / glycopyrronium
Estonian: Ultibro Breezhaler indakaterool/glükopürroonium
English: Why is Ultibro Breezhaler approved?
Estonian: Miks Ultibro Breezhaler heaks kiideti?
English: What are the risks associated with Ultibro Breezhaler?
Estonian: Mis riskid Ultibro Breezhaleriga kaasnevad?
English: For the full list of all side effects reported with Ultibro Breezhaler, see the package leaflet.
Estonian: Ultibro Breezhaleri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In the second study the average increase in FEV1 was 140 ml more with Ultibro Breezhaler treatment than with treatment with fluticasone and salmeterol.
Estonian: Teises uuringus suurenes FEV1 väärtus Ultibro Breezhaleri kasutamisel keskmiselt 140 ml rohkem kui flutikasooni ja salmeterooli kasutamisel.
English: The reduction in the rate of exacerbations was 10 to 12% higher with Ultibro Breezhaler than with tiotropium and glycopyrronium.
Estonian: Ultibro Breezhaleri korral harvenes ägenemine 10-12% rohkem kui tiotroopiumi ja glükopürrooniumi korral.
English: A third study studied the effects of Ultibro Breezhaler on the rate of exacerbations (flare-ups) patients experienced during 64 weeks of treatment when compared with treatment with glycopyrronium or tiotropium (other treatments for COPD).
Estonian: Kolmas uuring hindas Ultibro Breezhaleri toimet ägenemiste sagedusele patsientidel 64 ravinädala jooksul võrreldes glükopürrooniumi või tiotroopiumiga toimuva raviga (samuti kroonilise obstruktiivse kopsuhaiguse ravimid).
English: While one study compared the effects of Ultibro Breezhaler with those of placebo (a dummy inhalation), or indacaterol or glycopyrronium alone, the other study compared Ultibro Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD.
Estonian: Ühes uuringus võrreldi ravimit Ultibro Breezhaler platseeboga (näiv ravim) või eraldi indakaterooli või glükopürrooniumiga ning teises võrreldi ravimit Ultibro Breezhaler flutikasooni ja salmeterooli kombinatsiooniga, mis on kroonilise obstruktiivse kopsuhaiguse standardravi.
English: The active substances in Ultibro Breezhaler, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing in COPD.
Estonian: Ultibro Breezhaleri toimeained indakaterool ja glükopürroonium toimivad kumbki eri viisil, laiendades hingamisteid ja soodustades kroonilise obstruktiivse kopsuhaiguse korral hingamist.
English: Regarding its safety, Ultibro Breezhaler is comparable to indacaterol and glycopyrronium used as separate medicines.
Estonian: Ultibro Breezhaleri ohutus on võrreldav indakaterooli ja glükopürrooniumi ohutusega nende kasutamisel eraldi.
English: How is Ultibro Breezhaler used?
Estonian: Kuidas Ultibro Breezhalerit kasutatakse?
English: How does Ultibro Breezhaler work?
Estonian: Kuidas Ultibro Breezhaler toimib?
English: The recommended dose is one inhalation once a day of the powder content of a single capsule.
Estonian: Soovitatav annus on ühe kapsli pulbri üks inhalatsioon üks kord ööpäevas, iga päev samal kellaajal ja ravimi Ultibro Breezhaleri inhalaatori abil.
English: What benefits of Ultibro Breezhaler have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ultibro Breezhaleri kasulikkus?
English: Ultibro Breezhaler is available as capsules containing a powder for inhalation and can only be obtained with a prescription.
Estonian: Ravimit Ultibro Breezhaler turustatakse inhalatsioonipulbri kapslitena.
English: The
Estonian: ACOMPLIA
English: ACOMPLIA is taken as one tablet once a day, before breakfast.
Estonian: ACOMPLIAt võetakse üks tablett üks kord päevas enne hommikusööki.
English: The European Commission granted a marketing authorisation valid throughout the European Union for ACOMPLIA to sanofi-aventis on 19 June 2006.
Estonian: Euroopa Komisjon väljastas ACOMPLIA müügiloa, mis on kehtib kogu Euroopa Liidu territooriumil, ettevõttele sanofi-aventis 19. juunil 2006.
English: Medicinal product no longer authorised©EMEA 2007
Estonian: Ravimil on müügiluba lõppenud©EMEA 2007
English: The studies in smoking cessation did not show consistent results, and the effect of ACOMPLIA in this area was difficult to estimate.
Estonian: Suitsetamisest loobumisega seotud uuringud ei andnud paraku ühetaolisi tulemusi ning ACOMPLIA toimet selles valdkonnas oli raske hinnata.
English: The Committee recommended that ACOMPLIA be given marketing authorisation.
Estonian: Komitee soovitas anda ACOMPLIAle müügiloa.
English: Other information about ACOMPLIA:
Estonian: Muu teave ACOMPLIA kohta
English: Which measures are being taken to ensure the safe use of ACOMPLIA?
Estonian: Milliseid meetmeid võetakse, et tagada ACOMPLIA kasutamise ohutus?
English: Therefore, ACOMPLIA is not recommended as an aid for smoking cessation
Estonian: Seetõttu ei soovitata ACOMPLIAt suitsetamisest loobumise abivahendina.
English: It acts by blocking a specific type of receptor, the cannabinoid type 1 (CB1) receptors.
Estonian: See toimib blokeerides teatud tüüpi retseptoreid - kannabinoid-1 retseptoreid (CB-1).
English: The company that makes ACOMPLIA will put in place a programme to ensure that the medicine is used in patients who need it for health, rather than for cosmetic reasons, by providing educational packs for patients and doctors, and to monitor how the medicine is used.
Estonian: ACOMPLIAt valmistav ettevõte rakendab programmi, et tagada ravimi kasutamine patsientidel, kes vajavad seda tervislikel mitte kosmeetilistel põhjustel - pakkudes selleks patsientidele ja arstidele teavitusmaterjale - ning et jälgida, kuidas ravimit kasutatakse.
English: The company will use specific databases to monitor ACOMPLIA's side effects, especially those linked to the nervous system.
Estonian: Ettevõte kasutab ACOMPLIA kõrvalnähtude, eelkõige närvisüsteemiga seotud kõrvalnähtude jälgimiseks spetsiaalseid andmebaase.
English: ACOMPLIA is a medicine containing the active substance rimonabant.
Estonian: ACOMPLIA on ravim, mis sisaldab toimeainena rimonabanti.
English: The active substance in ACOMPLIA, rimonabant, is a cannabinoid receptor antagonist.
Estonian: ACOMPLIA toimeaine rimonabant on kannabinoidretseptori antagonist.
English: ACOMPLIA is used together with diet and exercise to treat adult patients:
Estonian: ACOMPLIAt kasutatakse koos dieedi ja kehaliste harjutustega järgmiste täiskasvanud patsientide raviks:
English: Patients who experience symptoms of depression should speak to their doctor and may need to stop treatment.
Estonian: Depressiooni sümptomitega patsiendid peavad pidama nõu arstiga ja peavad võib-olla ravi ACOMPLIAga katkestama.
English: What is the risk associated with ACOMPLIA?
Estonian: Millised on ACOMPLIAga kaasnevad riskid?
English: During the studies, the most common side effects with ACOMPLIA (seen in more than 1 patient in 10) were nausea (feeling sick) and infections of the upper respiratory tract.
Estonian: Uuringute käigus ACOMPLIAga kõige sagedamini kaasnenud kõrvalnähud (täheldatud rohkem kui ühel patsiendil kümnest) olid iiveldus ja ülemiste hingamisteede nakkused.
English: It must also not be used in patients with ongoing major depression or who are being treated with antidepressants, since it can increase the risk of depression, including thoughts about suicide in a small minority of patients.
Estonian: ACOMPLIAt ei tohi lisaks kasutada patsientidel, kellel on raske depressioon või keda ravitakse antidepressantidega, kuna ravim võib väikese hulga patsientide seas suurendada depressiooniohtu, sealhulgas enesetapumõtete ohtu.
English: ACOMPLIA should not be used in patients who may be hypersensitive (allergic) to rimonabant or any of the other ingredients, or in women who are breast feeding.
Estonian: ACOMPLIAt ei tohi kasutada patsientidel, kes võivad olla ülitundlikud (allergilised) rimonabandi või selle ravimi mis tahes muu koostisaine suhtes, ning last rinnaga toitvatel naistel.
English: Caution should be used when taking ACOMPLIA with some medicines, such as ketoconazole or itraconazole (anti-fungal medicines), ritonavir (used in HIV infection), or telithromycin or clarithromycin (antibiotics).
Estonian: Ettevaatlik tuleb olla ACOMPLIA kasutamisel koos mõningate teiste ravimitega, näiteks ketokonasooli või itrakonasooliga (seentevastased ravimid), ritonaviiriga (kasutatakse HIV-nakkuse korral) või telitromütsiini või klaritromütsiiniga (antibiootikumid).
English: After one year, all patients who received ACOMPLIA lost more weight than those who received placebo: they lost on average 4.9 kg more than placebo, except in the study in diabetic patients, where the difference in the weight loss was 3.9 kg.
Estonian: Ühe aasta möödudes olid ACOMPLIAt saanud patsiendid kaotanud kehakaalus rohkem kui need, kellele oli manustatud platseebot: nende kehakaal vähenes keskmiselt 4,9 kg võrra rohkem kui platseeborühma patsientidel, välja arvatud suhkurtõvega patsientide uuringus, kus kehakaalu vähenemise erinevus oli 3,9 kg.
English: Why has ACOMPLIA been approved?
Estonian: Miks ACOMPLIA heaks kiideti?
English: Four studies of ACOMPLIA in overweight and obese patients were carried out, involving almost 7,000 patients, whose weight at the start of the studies was on average 94 to 104 kg. One study looked more particularly at patients with abnormal levels of blood fat, and one at patients with type 2 diabetes.
Estonian: ACOMPLIA uurimiseks viidi läbi neli uuringut, mis hõlmasid peaaegu 7000 rasvunud ja ülekaalulist patsienti, kelle kehakaal oli uuringu alguses keskmiselt 94-104 kg. Ühes uuringus pöörati erilist tähelepanu vere ebanormaalse rasvasisaldusega patsientide ja ühes uuringus II tüüpi suhkurtõvega patsientide uurimisele.
English: For the full list of all side effects reported with ACOMPLIA, see the Package Leaflet.
Estonian: ACOMPLIA kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: What is ACOMPLIA?
Estonian: Mis on ACOMPLIA?
English: studies compared the effect of ACOMPLIA with that of a placebo (a dummy treatment) on weight loss over one to two years.
Estonian: Uuringutes võrreldi ACOMPLIA toimet platseebo (näiva ravimi) mõjuga kehakaalu langusele ühe kuni kahe aasta vältel.
English: The Committee decided that ACOMPLIA's benefits are greater than its risks when used, in addition to diet and exercise, to treat obese patients and overweight patients with risk factors such as type 2 diabetes or dyslipidaemia.
Estonian: Komitee otsustas, et ACOMPLIA kasulikkus selle kasutamisel lisaks dieedile ja liikumisele rasvunud patsientide ning ülekaaluliste ja selliste ohuteguritega nagu II tüüpi suhkurtõbi või düslipideemia patsientide raviks on suurem kui sellega kaasnevad riskid.
English: The Committee for Medicinal products for Human Use (CHMP) concluded that ACOMPLIA had shown its effectiveness in weight reduction in obese or overweight patients with associated risk factors.
Estonian: Inimtervishoius kasutatavate ravimite komitee jõudis järeldusele, et ACOMPLIA tõhusus rasvunud või ülekaaluliste ning kaasneva(te) ohuteguri(te)ga patsientide kehakaalu vähendamisel on tõendatud.
English: The effects of ACOMPLIA were first tested in experimental models before being studied in humans.
Estonian: Enne uuringuid inimestel kontrolliti ACOMPLIA toimet muude katsetega.
English: What benefit has ACOMPLIA shown during the studies?
Estonian: Milles seisneb uuringute põhjal ACOMPLIA kasulikkus?
English: The full EPAR for ACOMPLIA can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti ACOMPLIA kohta leiate siit.
English: How has ACOMPLIA been studied?
Estonian: Kuidas ACOMPLIAt uuriti?
English: How is ACOMPLIA used?
Estonian: Kuidas ACOMPLIAt kasutatakse?
English: What is ACOMPLIA used for?
Estonian: Milleks ACOMPLIAt kasutatakse?
English: Four studies of ACOMPLIA as a help to stop smoking were also carried out in over 7,000 patients, comparing it with placebo, and measuring the effect of the medicine given for 10 weeks (one year in one of the studies) on smoking cessation, and on relapses in the following year.
Estonian: Samuti viidi läbi veel neli uuringut, mis hõlmasid enam kui 7000 patsienti ja milles ACOMPLIAt vaadeldi suitsetamisest loobumise abivahendina, võrreldes seda platseeboga ning hinnates ravimi toimet, kusjuures
English: How does ACOMPLIA work?
Estonian: Kuidas ACOMPLIA toimib?
English: The studies lasted 12 weeks.
Estonian: Uuringud kestsid 12 nädalat.
English: Levitra vardenafil
Estonian: Levitra vardenafiil
English: What measures are being taken to ensure the safe and effective use of Levitra?
Estonian: Mis meetmed võetakse, et tagada Levitra ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levitra on 6 March 2003.
Estonian: Euroopa Komisjon andis Levitra müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. märtsil
English: A risk management plan has been developed to ensure that Levitra is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Levitra võimalikult ohutu kasutamine.
English: This was recorded in two questionnaires completed at home.
Estonian: Andmed koguti kahe kodus täidetava küsimustiku abil.
English: The full EPAR for Levitra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Levitra kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What is Levitra?
Estonian: Mis on Levitra?
English: For Levitra to be effective, sexual stimulation is required.
Estonian: Et Levitra oleks efektiivne, on vaja seksuaalset stimulatsiooni.
English: In all of the studies, the main measure of effectiveness was the ability to get and maintain an erection.
Estonian: Kõigis uuringuis oli efektiivsuse põhinäitaja võime saavutada ja säilitada erektsioon.
English: The most common side effect with Levitra (seen in more than 1 patient in 10) is headache.
Estonian: Levitra kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on peavalu.
English: Because Levitra has not been studied in the following group patients, they must not use the medicine:
Estonian: Et Levitrat ei ole uuritud järgmistel patsiendirühmadel, ei tohi seda kasutada:
English: Why has Levitra been approved?
Estonian: Miks Levitra heaks kiideti?
English: The recommended dose of Levitra is 10 mg, taken about 25 to 60 minutes before sexual activity.
Estonian: Levitra soovitatav annus on 10 mg, mis võetakse sisse ligikaudu 25-60 minutit enne suguühet.
English: Levitra tablets and orodispersible tablets were significantly more effective than placebo for all measures in all of the studies.
Estonian: Levitra tabletid ja suus dispergeeruvad tabletid olid kõigis uuringutes platseebost kõigi näitajate poolest oluliselt efektiivsemad.
English: The CHMP decided that Levitra's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Levitra kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Other information about Levitra:
Estonian: Muu teave Levitra kohta
English: The active ingredient of Levitra, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Estonian: Levitra toimeaine vardenafiil kuulub 5. tüüpi fosfodiesteraasi (PDE5) inhibiitoriteks nimetatavate ravimite rühma.
English: What is the risk associated with Levitra?
Estonian: Mis riskid Levitraga kaasnevad?
English: The dose of the film-coated tablets may be increased to a maximum of 20 mg or decreased to 5 mg, depending on the effectiveness of treatment and any side effects.
Estonian: Polümeerkattega tablettide annust võib suurendada 20 mg-ni või vähendada 5 mg-ni, olenevalt ravimi efektiivsusest ja võimalikest kõrvalnähtudest.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Levitra, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Levitra omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Levitra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Levitraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Levitra is a medicine that contains the active substance vardenafil.
Estonian: Levitra on ravim, mis sisaldab toimeainena vardenafiili.
English: It must also not be used in patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy or NAION).
Estonian: Samuti ei tohi seda kasutada patsiendid, kellel on kunagi esinenud silmanärvi verevarustushäirete (optilise mittearteriitse anterioosse isheemilise neuropaatia, NAION) tõttu nägemiskaotust.
English: Levitra is used to treat adult men (aged 18 years or over) with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity.
Estonian: Levitrat kasutatakse erektsioonihäirete (mida mõnikord nimetatakse impotentsuseks) raviks täiskasvanud (vähemalt 18-aastastel) meestel, kui nad ei suuda saavutada või säilitada rahuldavaks seksuaaleluks vajalikku peenise jäigastumist (erektsiooni).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levitra.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What benefit has Levitra shown during the studies?
Estonian: Milles seisneb uuringute põhjal Levitra kasulikkus?
English: The maximum recommended dosing frequency is one film-coated tablet or orodispersible tablet per day.
Estonian: Levitra suurim soovitatav annus on üks õhukese polümeerkattega tablett või suus dispergeeruv tablett ööpäevas.
English: The orodispersible tablets must be taken without liquid.
Estonian: Suus dispergeeruvad tabletid tuleb sisse võtta ilma vedelikuta.
English: Levitra must not be taken with ketoconazole and itraconazole (used to treat fungal infections) in men over 75 years of age, or with medicines called ‘HIV protease inhibitors' such as ritonavir or indinavir (used to treat HIV infection).
Estonian: Levitrat ei tohi kasutada koos ketokonasooli ja itrakonasooliga (seennakkuste ravimid) üle 75-aastased meestel, ega koos HIV-proteaasiinhibiitoritega, näiteks ritonaviiri ja indinaviiriga (HIV-nakkuse ravimid).
English: One of these studies was carried out in diabetic men and another in men who had had their prostate gland removed.
Estonian: Üks uuring toimus meestega, kellel oli diabeet (suhkurtõbi), ja üks meestega, kellel oli eesnääre eemaldatud.
English: If Levitra film-coated tablets are taken with a high fat meal, the onset of activity may be delayed.
Estonian: Levitra polümeerkattega tablettide manustamisel koos rasvase toiduga võib ravim mõjuda aeglaselt.
English: Two additional main studies compared orodispersible tablets with placebo in 701 men aged 21 to 84 years
Estonian: Kahes lisauuringus võrreldi suus dispergeeruvaid tablette platseeboga (kokku 701 meesosalejat vanuses 2183 eluaastat).
English: Levitra must not be used in people who are hypersensitive (allergic) to vardenafil or any of the other ingredients.
Estonian: Levitrat ei tohi kasutada patsiendid, kes on vardenafiili või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: This document is a summary of the European public assessment report (EPAR) for Levitra.
Estonian: See on ravimi Levitra Euroopa avaliku hindamisaruande kokkuvõte.
English: It must not be used when sexual activity is inadvisable, such as in men with severe heart disease.
Estonian: Levitrat ei tohi kasutada patsiendid, kellel suguelu ei ole soovitatav (nt raske südamehaigusega mehed).
English: By blocking the breakdown of cGMP, Levitra restores erectile function.
Estonian: cGMP lagundamist blokeerides taastab Levitra erektsioonivõime.
English: Levitra tablets were compared with placebo (a dummy treatment) in four main studies including a total of 2,431 men with erectile dysfunction aged 20 to 83 years.
Estonian: Levitra tablette uuriti neljas põhiuuringus, milles osales kokku 2431 erektsioonihäiretega 20-83aastast meest ja kus Levitrat võrreldi platseeboga (näiva ravimiga).
English: For the full list of all side effects reported with Levitra, see the package leaflet.
Estonian: Levitra kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How does Levitra work?
Estonian: Kuidas Levitra toimib?